A global systematic analysis and statistical evaluation of prognostic prediction models for non-small cell lung cancer
Authors:
- Yuan ChenYCYuan Chen
Open Access
- 1 January 2026
- journal article
- Published by Innovation Press Co., Limited in The Innovation Medicine
- Vol. 4 (1) , 100195-1-100195-13
Abstract
Prognostic prediction models can aid clinical decision-making for high-risk non-small cell lung cancer (NSCLC) patients. We conducted a systematic search across multiple databases and evaluated eligible studies using PRISMA and PROBAST checklists. Of 28,833 references screened, 233 studies describing 268 models were included. Among them, 89 underwent external validation; 67 (75.28%) were classified with high risk for bias. Most models were developed in North America (45.06%). The median area under the receiver operating characteristic curve (AUC) for 1-, 3-, and 5-year predictions were 0.759, 0.720, and 0.691, respectively. The most common predictors were age (54.85%) and stage (58.21%). And, 47.01% of models were sex-specific. Recently, easily accessible radiomic features have been increasingly used in statistical modeling compared to molecular omics. Models integrating radiomic and clinical features showed potential for improved performance (1-, 3-, and 5-year AUCs: 0.931, 0.985, 0.942). Model discrimination varied across different studies, and there is a lack of model calibration and clinical utility. This review highlights advances and limitations in NSCLC prognostic models. To enhance model reliability and generalizability, it remains crucial to adhere to the TRIPOD guideline to perform prediction model study, and to emphasize comprehensive model validation and bias-reduction strategies. Following a step-by-step guide to develop and validate clinical prediction models by Efthimiou, et al. (BMJ, 2024), along with a multifaceted, multidisciplinary and multi-regional approach, is the key way to facilitate the development and clinical application of qualified models.Keywords
This publication has 66 references indexed in Scilit:
- Optimal Vasopressin Initiation in Septic ShockJAMA, 2025
- Non‐small cell lung cancer in ChinaCancer Communications, 2022
- Construction and validation of a nomogram based on N6‐Methylandenosine‐related lncRNAs for predicting the prognosis of non‐small cell lung cancer patientsCancer Medicine, 2022
- Prognosis biomarker and potential therapeutic target CRIP2 associated with radiosensitivity in NSCLC cellsBiochemical and Biophysical Research Communications, 2021
- Artificial intelligence in gynecologic cancers: Current status and future challenges – A systematic reviewArtificial Intelligence in Medicine, 2021
- Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers With Gene-Gene Interactions and Main EffectsChest, 2020
- High expression levels of pyrimidine metabolic rate–limiting enzymes are adverse prognostic factors in lung adenocarcinoma: a study based on The Cancer Genome Atlas and Gene Expression Omnibus datasetsPurinergic Signalling, 2020
- A novel strategy of integrated microarray analysis identifies CENPA, CDK1 and CDC20 as a cluster of diagnostic biomarkers in lung adenocarcinomaCancer Letters, 2018
- Establishment of an Adjusted Prognosis Analysis Model for Initially Diagnosed Non–Small-Cell Lung Cancer With Brain Metastases From Sun Yat-Sen University Cancer CenterClinical Lung Cancer, 2017
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted DrugsJAMA, 2014